BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 15562929)

  • 1. Role of N-acetylcysteine in prevention of contrast-induced nephropathy after cardiovascular procedures: a meta-analysis.
    Misra D; Leibowitz K; Gowda RM; Shapiro M; Khan IA
    Clin Cardiol; 2004 Nov; 27(11):607-10. PubMed ID: 15562929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast.
    Boccalandro F; Amhad M; Smalling RW; Sdringola S
    Catheter Cardiovasc Interv; 2003 Mar; 58(3):336-41. PubMed ID: 12594698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of hydration with or without n-acetylcysteine on contrast induced nephropathy in patients undergoing coronary angiography and percutaneous coronary intervention.
    Awal A; Ahsan SA; Siddique MA; Banerjee S; Hasan MI; Zaman SM; Arzu J; Subedi B
    Mymensingh Med J; 2011 Apr; 20(2):264-9. PubMed ID: 21522098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Contrast nephropathy in cardiac procedures: no advantages with prophylactic use of N-acetylcysteine (NAC)].
    Vallero A; Cesano G; Pozzato M; Garbo R; Minelli M; Quarello F; Formica M
    G Ital Nefrol; 2002; 19(5):529-33. PubMed ID: 12439841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usefulness of N-acetylcysteine or ascorbic acid versus placebo to prevent contrast-induced acute kidney injury in patients undergoing elective cardiac catheterization: a single-center, prospective, randomized, double-blind, placebo-controlled trial.
    Brueck M; Cengiz H; Hoeltgen R; Wieczorek M; Boedeker RH; Scheibelhut C; Boening A
    J Invasive Cardiol; 2013 Jun; 25(6):276-83. PubMed ID: 23735352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes of contrast-induced nephropathy in patients undergoing percutaneous coronary intervention: a prospective, multicenter, randomized study to analyze the effect of hydration and acetylcysteine.
    Chen SL; Zhang J; Yei F; Zhu Z; Liu Z; Lin S; Chu J; Yan J; Zhang R; Kwan TW
    Int J Cardiol; 2008 Jun; 126(3):407-13. PubMed ID: 17651830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of N-acetylcysteine for prevention of contrast nephropathy in patients with moderate to severe renal insufficiency: a randomized trial.
    Fung JW; Szeto CC; Chan WW; Kum LC; Chan AK; Wong JT; Wu EB; Yip GW; Chan JY; Yu CM; Woo KS; Sanderson JE
    Am J Kidney Dis; 2004 May; 43(5):801-8. PubMed ID: 15112170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acetylcysteine for prevention of contrast nephropathy: meta-analysis.
    Birck R; Krzossok S; Markowetz F; Schnülle P; van der Woude FJ; Braun C
    Lancet; 2003 Aug; 362(9384):598-603. PubMed ID: 12944058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-acetylcysteine fails to prevent renal dysfunction and oxidative stress after noniodine contrast media administration during percutaneous coronary interventions.
    Buyukhatipoglu H; Sezen Y; Yildiz A; Bas M; Kirhan I; Ulas T; Turan MN; Taskin A; Aksoy N
    Pol Arch Med Wewn; 2010 Oct; 120(10):383-9. PubMed ID: 20980943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of radiocontrast-induced nephropathy with N-acetylcysteine in patients undergoing coronary angiography.
    Tadros GM; Mouhayar EN; Akinwande AO; Campbell B; Wood C; Blankenship JA
    J Invasive Cardiol; 2003 Jun; 15(6):311-4. PubMed ID: 12777667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of combination therapy of high-dose oral N-acetylcysteine and intravenous sodium bicarbonate hydration with individual therapies in the reduction of Contrast-induced Nephropathy during Cardiac Catheterisation and Percutaneous Coronary Intervention (CONTRAST): A multi-centre, randomised, controlled trial.
    Chong E; Poh KK; Lu Q; Zhang JJ; Tan N; Hou XM; Ong HY; Azan A; Chen SL; Chen JY; Ali RM; Fang WY; Lau TW; Tan HC
    Int J Cardiol; 2015 Dec; 201():237-42. PubMed ID: 26301645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of nicorandil treatment for prevention of contrast-induced nephropathy in high-risk patients undergoing cardiac catheterization: A prospective randomized controlled trial.
    Iranirad L; Hejazi SF; Sadeghi MS; Jang SA
    Cardiol J; 2017; 24(5):502-507. PubMed ID: 28281738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy.
    Kelly AM; Dwamena B; Cronin P; Bernstein SJ; Carlos RC
    Ann Intern Med; 2008 Feb; 148(4):284-94. PubMed ID: 18283206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized controlled trial comparing hydration therapy to additional hemodialysis or N-acetylcysteine for the prevention of contrast medium-induced nephropathy: the Dialysis-versus-Diuresis (DVD) Trial.
    Reinecke H; Fobker M; Wellmann J; Becke B; Fleiter J; Heitmeyer C; Breithardt G; Hense HW; Schaefer RM
    Clin Res Cardiol; 2007 Mar; 96(3):130-9. PubMed ID: 17180572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy of N-acetylcysteine plus sodium bicarbonate in the prevention of contrast-induced nephropathy after cardiac catheterization and percutaneous coronary intervention: A meta-analysis of randomized controlled trials.
    Zhao SJ; Zhong ZS; Qi GX; Tian W
    Int J Cardiol; 2016 Oct; 221():251-9. PubMed ID: 27404685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-acetylcysteine and/or ascorbic acid versus placebo to prevent contrast-induced nephropathy in patients undergoing elective cardiac catheterization: The NAPCIN trial; A single-center, prospective, randomized trial.
    Habib M; Hillis A; Hammad A
    Saudi J Kidney Dis Transpl; 2016 Jan; 27(1):55-61. PubMed ID: 26787567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylaxis of contrast-induced nephropathy in patients undergoing coronary angiography.
    MacNeill BD; Harding SA; Bazari H; Patton KK; Colon-Hernadez P; DeJoseph D; Jang IK
    Catheter Cardiovasc Interv; 2003 Dec; 60(4):458-61. PubMed ID: 14624421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous N-acetylcysteine plus high-dose hydration versus high-dose hydration and standard hydration for the prevention of contrast-induced nephropathy: CASIS--a multicenter prospective controlled trial.
    Koc F; Ozdemir K; Kaya MG; Dogdu O; Vatankulu MA; Ayhan S; Erkorkmaz U; Sonmez O; Aygul MU; Kalay N; Kayrak M; Karabag T; Alihanoglu Y; Gunebakmaz O
    Int J Cardiol; 2012 Mar; 155(3):418-23. PubMed ID: 21106264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography. A randomized controlled trial and review of the current literature.
    Goldenberg I; Shechter M; Matetzky S; Jonas M; Adam M; Pres H; Elian D; Agranat O; Schwammenthal E; Guetta V
    Eur Heart J; 2004 Feb; 25(3):212-8. PubMed ID: 14972421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of contrast-induced nephropathy in vascular patients undergoing angiography: a randomized controlled trial of intravenous N-acetylcysteine.
    Rashid ST; Salman M; Myint F; Baker DM; Agarwal S; Sweny P; Hamilton G
    J Vasc Surg; 2004 Dec; 40(6):1136-41. PubMed ID: 15622367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.